University of Iowa Health Care first to adopt IDx-DR in a diabetes care setting
IDx-DR, the first autonomous AI diagnostic system cleared by the FDA, is now being used in patient care at University of Iowa Health Care.
No fooling new DNA test on smoking, alcohol
CORALVILLE — When it comes to admitting how much they smoke or drink, people aren’t always the most truthful.
FDA permits marketing of IDx-DR for automated detection of diabetic retinopathy in primary care
IDx, a privately-held AI diagnostics company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company’s De Novo request to market IDx-DR, an AI-based diagnostic system for the autonomous detection of diabetic retinopathy, a leading cause of blindness. IDx-DR is the first autonomous, AI-based diagnostic system authorized for commercialization by the FDA.
FDA approves first product for Coralville-based IDx
IDx, a University of Iowa spinout company based in Coralville, has received FDA approval to market IDX-DR, the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes.
SynderBio takes top company award at biotech showcase
Coralville-based SynderBio was awarded the top company award at this year's Partnering For Growth Biotech Innovation Showcase held in Ankeny on Tuesday.
KLAS Report Ranks MediRevv Second in Extended Business Office for Fourth Consecutive Year
THIS MARKS THE FIFTH YEAR THAT MEDIREVV HAS BEEN RANKED IN THE TOP THREE!
Coralville, IA – February 28, 2018– MediRevv, a healthcare revenue cycle management company, has been ranked second in the “Extended Business Office” category of the 2017/2018 Best in KLAS: Software and Services Report, February 2018.
MediRevv debuted on the KLAS list in 2013/2014 ranking third. In the 2014/2015 Best in KLAS report, they moved into the second position for the first time. Of note, MediRevv has held the second place ranking for four years running.
KemPharm Announces FDA Approval of Apadaz™ (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain
CORALVILLE, Iowa, Feb. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Apadaz™ for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Apadaz is an immediate release (IR) combination of KemPharm’s prodrug, benzhydrocodone, and acetaminophen (APAP).
General Dynamics to Acquire CSRA for $9.6 Billion
- Combination creates the premier provider of high-tech IT solutions to Government Technology Services market
- With approximately $9.9 billion in revenue and strong double-digit EBITDA margins, the combined GDIT and CSRA is well-positioned to serve its customers’ current and evolving mission requirements
- Expected to generate run-rate pre-tax cost synergies of approximately 2% of combined sales by 2020
- Accretive to earnings and free cash flow per share in 2019
Voxello Announces their 4th Major Distribution Partnership
February 19, 2018 08:00 AM Eastern Standard Time
CORALVILLE, Iowa--(BUSINESS WIRE)--Today, Voxello, patient-provider engagement company specializing in solutions for critically ill patients, announced its fourth major distribution partnership with ASCC, Inc., a major U.S. distributor. ASCC partners with hospitals, long term care facilities and clinics in the Western Pennsylvania and Eastern Ohio regions and is now strategically positioned to distribute Voxello’s cutting-edge noddle® technology in this important market.
Pages
